Agilent Shares Up 8 Percent on Strong Growth in Q3 Revenue, Profit | GenomeWeb
NEW YORK (GenomeWeb News) – Shares in Agilent were up 8.14 percent, or $2.32, at $30.79 in mid-afternoon trading after the company yesterday reported a surge in third-quarter revenue and profit.
 
As GenomeWeb News reported this morning, Agilent said total revenues for the three months ended June 30 increased 17 percent to $1.45 billion from $1.24 billion in the same quarter last year. The company’s net income rose 118 percent to $227 million from $104 million a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.